reports
GE HealthCare reports third quarter 2024 financial results
CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today reported financial results for the third quarter ended September 30, 2024. GE HealthCare President and CEO Peter Arduini said, “In the third quarter, we reported sales and orders growth of 1% globally. Both sales and orders grew in the mid-single digits excluding China, with particular strength in the U.S. across all segments. Pharmaceutical Diagnostics also delivered solid performance, driven by healthy procedure volumes. Ongoing lean initiatives across the organization are delivering better value to patients and customers and hav...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of GE HealthCare Technologies Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 23 October 2024 in which we reassessed the appropriateness of the ratings i...
GE HealthCare announces CareIntellect for Oncology, harnessing AI to g...
CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced CareIntellect for Oncology, a new cloud-first application that brings together multi-modal patient data from disparate systems into a single view, using generative AI to summarize clinical notes and reports. The application also surfaces relevant data allowing care teams to quickly understand disease progression and flag potential deviations from the treatment plan to help the clinician determine potential next steps and inform proactive interventions. The application, which is planned to be available to customers in U.S. ...
GE HealthCare Announces AI Innovation Lab Showcasing Five New Research...
CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced a new AI Innovation Lab, an initiative designed to accelerate early-concept AI innovations within the company. These projects are one part of GE HealthCare’s broader AI and digital strategy, which is focused on integrating AI into medical devices, building AI applications that enhance decision-making across the care journey and disease states, and using AI to support better outcomes and operational efficiencies system-wide. The company’s investment in cloud technology underpins this strategy, providing the computing power ...
GE HealthCare, the GE HealthCare Foundation, and the Charles Antetokou...
MILWAUKEE--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC), the GE HealthCare Foundation, and the Charles Antetokounmpo Family Foundation (CAFF), teamed up to launch a new philanthropic endeavor, Powering Milwaukee Forward, aimed at improving access to basic needs within Milwaukee’s underserved communities. The initiative will grant 10 area nonprofits a total of $1 million. “The City of Milwaukee has done so much for me and my family – but I know there are so many in this community who struggle to access basic needs,” said Giannis Antetokounmpo, Milwaukee Bucks power forward and founder of CAF...
GE HealthCare announces major academic medical center as first custome...
CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced a new tile for its Command Center Software: Hospital Pulse. Hospital Pulse Tile pulls in real-time information from across departments to quickly surface the most vital information about a healthcare system’s operations in a customizable dashboard designed to give operation leaders the quick “pulse check” they need to make adjustments throughout the day. For example, the tile can be configured to show how the number of emergency department admissions today as compared to a six-month median or to show what the maximum post-...
A New Theranostics Center of Excellence in Europe: GE HealthCare and U...
CHICAGO--(BUSINESS WIRE)-- With the aim of increasing access to precision care, GE HealthCare is proud to collaborate with University Medicine Essen (UME) in the establishment of a new Theranostics Center of Excellence. The Center will be outfitted with the latest technologies and solutions to support the clinical practice and advanced research of more personalized approaches to cancer care in Germany and around the world. Cancerous diseases continue to threaten the lives of patients, with over 10 million new cancer cases diagnosed annually.i Fortunately, the advancement of precision diagnost...
GE HealthCare introduces easy-to-use, easy-to-learn, easy-to-diagnose ...
CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced the launch of the new Versana Premier™, the latest release within the Versana ultrasound family of reliable, affordable, easy-to-use, and versatile ultrasound systems. Versana Premier offers automation and AI-enabled productivity tools to improve workflow and clinical features designed to enhance clinical efficiency and accuracy, all while delivering an effortless user experience and helping clinicians best meet their patient needs.i The Versana Premier is designed to meet the multi-purpose needs of healthcare professional...
GE HealthCare Accelerates Artificial Intelligence Adoption With New Of...
CHICAGO--(BUSINESS WIRE)-- GE HealthCare integrates third party artificial intelligence (AI)-enabled application orchestration feature into True PACS and Centricity PACS. 1 In collaboration with Blackford, the new AI-enabled offerings help radiologists with their workload which could help lead to quicker diagnosis and treatment for patients. The collaboration is intended to offer health care providers an AI-enabled platform with a catalogue of third-party AI applications that span across various clinical area use cases, ranging from mammography to lung scans. 2 Many clinicians are burnt out a...
GE HealthCare to announce third quarter 2024 results on October 30, 20...
CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) will announce its third quarter 2024 financial results before the market opens on Wednesday, October 30, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at . The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global...
GE HealthCare takes key role in new consortium to revolutionize cancer...
CHICAGO--(BUSINESS WIRE)-- GE HealthCare announces the commencement, and its leading industrial role, in Thera4Care, an initiative aimed at revolutionizing the use of theranostics to broaden patient access in Europe. The €25.3 million project gathers 29 partners from top European academic and clinical sites, small and medium-sized enterprises, and patient advocacy groups. Cancer is the leading cause of death worldwide, accounting for nearly ten million deaths in 2022. By 2050, the global burden is expected to grow to 35 million new cancer cases, which is due, in part, to population growth and...
GE HealthCare Announces Phase I Results for a First-of-its-Kind Macroc...
CHALFONT ST GILES, England--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) has today announced the completion of its Phase I clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. The results, which will be used to support ongoing clinical development, concluded that in a first-in-human study, this manganese-based contrast agent was well tolerated with no serious adverse events, dose-limiting toxicities or clinically relevant findings reported, according to an abstract presented at the 2024 bi-annual Contrast Media Rese...
GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) in...
ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of Flyrcado™ (flurpiridaz F 18) injection, a first of its kind positron emission tomography myocardial perfusion imaging (PET MPI) agent, for the detection of coronary artery disease (CAD). Indicated for patients with known or suspected CAD, Flyrcado delivers higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) MPI, the predominant procedure used in nuclear cardiology today. Flyrcado, which can be manu...
GE HealthCare Showcases the Latest AI-enhanced Radiation Therapy Solut...
CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced its latest innovations in radiation oncology that will be showcased at the American Society for Radiation Oncology (ASTRO) 2024 conference in Washington, DC. These novel solutions aim to improve the entirety of the radiation therapy workflow for clinicians and cancer patients. It is estimated that 470,000 patients receive radiotherapy each year in the U.S. and more than half of patients with cancer will receive radiotherapy.i The silver lining is, that in recent years, improvements in diagnosis, therapy, and supportive ca...
GE HealthCare introduces elevated Venue point of care ultrasound solut...
CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced the launch of enhanced Venue ultrasound systems and a new solution setting the pace of point-of-care ultrasound (POCUS): Venue Sprint. The Venue Sprint is a new ultrasound device designed for maximum portability that combines the powerful, familiar Venue software and AI-enabled tools, uncompromised image quality, and wireless probe capability with Vscan Air handheld ultrasound systems. Other Venue family ultrasound systems will also now offer wireless probe connectivity, supplementary advanced clinical tools and the latest...
GE HealthCare announces cash dividend for third quarter of 2024
CHICAGO--(BUSINESS WIRE)-- The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the third quarter of 2024 payable on November 15, 2024 to all shareholders of record as of October 18, 2024. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and pat...
GE HealthCare Technologies Inc. Prices Upsized Secondary Offering of 1...
CHICAGO--(BUSINESS WIRE)-- GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 15,000,000 shares of its common stock (the “GEHC Shares”) at a public offering price of $86.00 per share. The Offering was upsized from the previously announced offering size of 10,000,000 GEHC Shares. GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchang...
GE HealthCare Technologies Inc. Commences Secondary Offering of 10,000...
CHICAGO--(BUSINESS WIRE)-- GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the launch of a secondary underwritten public offering (the “Offering”) of 10,000,000 shares of its common stock (the “GEHC Shares”). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shares in the Offering or from the debt-for-equity exchange (as described below). Prior to the closing of the Offering, GE Aerospace (General Electric Company) is expected to exchange the GEHC Shares for indebtedness of GE A...
GE HealthCare Showcases Latest AI-Enhanced Cardiology Solutions to Ena...
CHICAGO--(BUSINESS WIRE)-- Today, GE HealthCare (Nasdaq: GEHC) announced the CE marks of its Vscan Air™ SL wireless handheld ultrasound system with Caption AI™ (Vscan Air SL with Caption AI), an artificial intelligence (AI)-driven software for rapid cardiac assessments at the point of care, as well as ECG-less Cardiac computed tomography (CT) scanning on its Revolution Apex™ platform, which allows clinicians to acquire cardiac images without the aid of the patients’ electrocardiogram (ECG) signal/trace. Both technologies will be showcased at the , in London, August 30-September 2, 2024. Card...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.